Virtus Biotech Clinical Trials ETF
21 hedge funds and large institutions have $19M invested in Virtus Biotech Clinical Trials ETF in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
17% more capital invested
Capital invested by funds: $16.2M → $19M (+$2.8M)
17% more funds holding
Funds holding: 18 → 21 (+3)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.2% less ownership
Funds ownership: 41.56% → 40.35% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
+$211K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$190K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$153K |
| 4 |
LPL Financial
San Diego,
California
|
+$112K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$93.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.4M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$463K |
| 3 |
Morgan Stanley
New York
|
-$160K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$160K |
| 5 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$50.9K |
BBC Hedge Fund Activity: Q4 2020 in Review
21 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2020, worth a combined $19M — up 17% from $16.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BBC positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was BHF RG Capital, opening a new position worth an estimated $211K. The largest seller was Susquehanna International Group, cutting an estimated $1.4M.
- 21 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2020, up from 18 in Q3 2020.
- Funds reported $19M of Virtus Biotech Clinical Trials ETF stock for Q4 2020, up 17% quarter-over-quarter.
- 5 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2020 and 2 closed out, a net change of +3 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2020 was BHF RG Capital, an estimated $211K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2020 was Susquehanna International Group, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2020.